Cushing`s Syndrome Diagnostics and Treatment

Cushing`s Syndrome Diagnostics and Treatment

Global Cushing`s Syndrome Diagnostics and Treatment Market to Reach US$819.7 Million by 2030

The global market for Cushing`s Syndrome Diagnostics and Treatment estimated at US$493.4 Million in the year 2023, is expected to reach US$819.7 Million by 2030, growing at a CAGR of 7.5% over the analysis period 2023-2030. Cushing`s Syndrome Treatment, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$473.9 Million by the end of the analysis period. Growth in the Cushing`s Syndrome Diagnostics segment is estimated at 9.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$135.2 Million While China is Forecast to Grow at 7.0% CAGR

The Cushing`s Syndrome Diagnostics and Treatment market in the U.S. is estimated at US$135.2 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$126.8 Million by the year 2030 trailing a CAGR of 7.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.8% and 6.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.3% CAGR.

Global Cushing`s Syndrome Diagnostics and Treatment Market - Key Trends and Drivers Summarized

What Is Cushing`s Syndrome and How Do We Detect It?

Cushing`s syndrome is a disorder that arises from excessive levels of cortisol in the body. Typically caused by medications such as glucocorticoids or by tumors that produce either cortisol or ACTH (adrenocorticotropic hormone), the syndrome manifests with distinctive symptoms such as rapid weight gain, especially in the face (moon face), back (buffalo hump), and midsection. Diagnosing Cushing’s syndrome is complex and involves a series of tests including urine cortisol tests, saliva tests for late-night cortisol levels, and blood ACTH measurements. Imaging studies like CT scans or MRI are also employed to identify the presence of tumors on the pituitary or adrenal glands. Early and accurate diagnosis is critical as it significantly influences the management and outcome of the treatment.

How Is Cushing`s Syndrome Treated?

Treatment of Cushing’s syndrome depends largely on the underlying cause. Surgery is the most common treatment for tumor-induced Cushing’s syndrome, aiming to remove the tumor completely, whether it is located on the pituitary gland (most common) or the adrenal glands. If surgery is not feasible or fails to remove the tumor entirely, radiation therapy may be an option. Medications can also be used to control cortisol production when surgery and radiation are not viable. These treatments aim to normalize cortisol levels, reduce the risk of complications, and improve quality of life, addressing both the hormonal balance and the symptoms caused by the excess cortisol.

What Are the Challenges and Innovations in Managing Cushing`s Syndrome?

Despite advancements, managing Cushing`s syndrome presents several challenges, including accurate diagnosis and managing the recurrence of the disease. Innovations in treatment and management have been significant, with the development of new pharmacological options that offer better control of cortisol levels. There is also ongoing research into more effective and less invasive surgical techniques, as well as improved radiation therapies that target only the affected tissues, reducing side effects. Genetic research is uncovering the reasons why some people develop these tumors, which is leading to more personalized treatment approaches.

What Drives the Growth in the Cushing’s Syndrome Market?

The growth in the Cushing’s syndrome market is driven by several factors, including advances in diagnostic technologies, increased awareness of the syndrome, and improvements in treatment modalities. Enhanced imaging technologies and more sensitive biochemical markers have made it possible to diagnose the syndrome earlier and with greater accuracy. Additionally, the rise in healthcare expenditure globally and the increasing prevalence of diseases that can induce Cushing`s syndrome, such as obesity and type 2 diabetes, are contributing to the market expansion. The development of new drugs that more effectively control cortisol levels with fewer side effects is also a significant driver, appealing to a broader range of patients and healthcare providers alike. These factors collectively foster a dynamic growth environment for the market, ensuring ongoing investment and research in the field.

Select Competitors (Total 44 Featured) -

• Corcept Therapeutics, Inc.
• HRA Pharma
• Novartis AG
• Orphagen Pharmaceuticals, Inc.
• Strongbridge Biopharma

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.